International News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Mad Cow disease: Filtration technology in development by Pall Corp. reduces infectious vCJD (variant Creutzfeldt-Jakob disease, the human variant of bovine spongiform encephalopathy) prions in blood below the detection limit of current methods, company announces March 18. Pall will submit a regulatory application in Europe by year-end for its vCJD infectivity assay. Separately, the European Commission endorses InPro's automated conformation-dependent immunoassay (aCDI) and the Prionics-Check luminescence immunoassay (LIA) for BSE March 14. Manufactured by Pierce Biotechnology, the LIA is slated for EU launch in the second quarter...
You may also be interested in...
Prion Diagnostics Coming to Life? New Study Suggests CJD Potential
NIH-funded researchers maintain that recent study results showing highly sensitive detection of Creutzfeldt-Jakob disease (CJD) in deceased humans suggest a promising method for in vitro prion disease testing in living tissue
Prion Diagnostics Coming to Life? New Study Suggests CJD Potential
NIH-funded researchers maintain that recent study results showing highly sensitive detection of Creutzfeldt-Jakob disease (CJD) in deceased humans suggest a promising method for in vitro prion disease testing in living tissue
TriPath Expanded Pap Labeling Data Claim Closes Gap With Cytyc
TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy